BAY3401016; Biomarker Study Alport

NCT ID: NCT07211685

Last Updated: 2025-11-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-02

Study Completion Date

2028-07-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alport syndrome (AS) is a rare genetic condition that causes kidney disease, hearing loss, and eye abnormalities that occur due to changes in specific genes (COL4A3, COL4A4, and COL4A5). These genes help in producing an important protein called collagen. People with AS have a high risk of developing chronic kidney disease (CKD), a condition in which there is progressive loss in kidney function over time. The kidneys soon lose their ability to remove waste products from the body properly, resulting in end-stage kidney disease. A common sign of decreasing kidney function is the presence of excess protein in the urine that is not usually found with healthy kidneys. This condition is known as proteinuria. The study drug, BAY 3401016 (a monoclonal antibody), is a type of medicine that blocks a protein called Semaphorin 3A (Sema3A), which is thought to be involved in causing kidney damage in AS. By blocking the action of the Sema3A protein, BAY 3401016 may prevent proteinuria and slow down the loss in kidney function due to AS.

The main purpose of this study is to learn more about how well BAY 3401016 works in slowing down the loss in kidney function in adults with a rapidly progressing AS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alport Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two parallel groups (BAY 3401016 and placebo)
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BAY 3401016

BAY 3401016 weekly for 24 weeks in addition to background therapy if eligible

Group Type EXPERIMENTAL

BAY 3401016

Intervention Type BIOLOGICAL

BAY 3401016

Placebo

Placebo weekly for 24 weeks in addition to background therapy if eligible

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo to BAY 3401016

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BAY 3401016

BAY 3401016

Intervention Type BIOLOGICAL

Placebo

Placebo to BAY 3401016

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must be 18 to 45 years of age inclusive
* Participants with AS, either XLAS (male) or ARAS (male or female)
* eGFR ≥ 45 mL/min/1.73m2
* UACR ≥ 500mg/g

Exclusion Criteria

* Chronic kidney disease is different from AS
* Clinically significant illness that could have influence on the safety of the participant and/or interfere with the study objectives
* History or current existence of malignancy
* Participants with history of severe allergies, multiple drug allergies or non-allergic drug reactions including allergies affecting the lower respiratory tract - allergic asthma, allergies requiring therapy with corticosteroids or urticaria
* Participants with active skin disorders (e.g. atopic dermatitis, severe acne)
* Systolic blood pressure above 140 mmHg
* Diastolic blood pressure above 90 mmHg
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bayer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nephrology Clinic at The Kirklin Clinic of UAB Hospital

Birmingham, Alabama, United States

Site Status

The Peggy and Harold Katz Family Drug Discovery Center - Nephrology

Miami, Florida, United States

Site Status

Center for Advanced Pediatrics - Nephrology

Atlanta, Georgia, United States

Site Status

Cardio Renal Institute

Chubbuck, Idaho, United States

Site Status

Tufts Medical Center | Nephrology Department

Boston, Massachusetts, United States

Site Status

Renal Disease Research Institute | Landry

Dallas, Texas, United States

Site Status

Hospital Británico

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Site Status

Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Site Status

Centro de Rehabilitacion Cardiovascular | San Luis, Argentina

San Luis, San Luis Province, Argentina

Site Status

Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares S.A.

Santa Fe, , Argentina

Site Status

St. Joseph's Healthcare - Hamilton

Hamilton, Ontario, Canada

Site Status

London Health Sciences Centre (LHSC) - University Hospital

London, Ontario, Canada

Site Status

Lakeridge Health-Oshawa

Oshawa, Ontario, Canada

Site Status

McGill University Health Centre - Glen Site

Montreal, Quebec, Canada

Site Status

CHU de Québec-Université Laval

Québec, Quebec, Canada

Site Status

Peking University First Hospital - Department of Pediatrics

Beijing, Beijing Municipality, China

Site Status

Children's Hospital of Chongqing Medical University - Department of Nephrology

Chongqing, Chongqing Municipality, China

Site Status

The First Affiliated Hospital, Sun Yat-sen University - Department of Pediatrics

Guangzhou, Guangdong, China

Site Status

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology - Pediatric Nephrology and Immunology

Wuhan, Hubei, China

Site Status

Children's Hospital, Zhejiang University School of Medicine - Department of Nephrology

Hangzhou, Zhejiang, China

Site Status

Fakultní nemocnice Hradec Kralové - Nefrologická klinika

Hradec Králové, , Czechia

Site Status

Všeobecná fakultní nemocnice v Praze - Klinika nefrologie

Prague, , Czechia

Site Status

CHU bordeaux - Hopital Pellegrin - Service de Nephrologie-Transplantation-Dialyse-Aphereses

Bordeaux, , France

Site Status

CHU de Brest - Hopital La Cavale Blanche - Service de Nephorologie-Hémodialyse-Transplantation

Brest, , France

Site Status

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades - Service d'Hopital De Jour Néphrologie adulte

Paris, , France

Site Status

Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital de Rangueil - Nephrologie et transplantation d'organes

Toulouse, , France

Site Status

Universitaetsmedizin Goettingen (UMG) - Klinik fuer Nephrologie und Rheumatologie

Göttingen, Lower Saxony, Germany

Site Status

Universitaetsklinikum Koeln - Klinik II fuer Innere Medizin - Nephrologie, Rheumatologie, Diabetologie, Innere Medizin

Cologne, North Rhine-Westphalia, Germany

Site Status

Charité Mitte - Nephrologie und Internistische Intensivmedizin

Berlin, , Germany

Site Status

Universitaetsklinikum Erlangen - Medizinische Klinik 4, Nephrologie, Hypertensiologie

Erlangen, , Germany

Site Status

Mavani Research Center

Ahmedabad, Gujarat, India

Site Status

K.G. Hospital

Coimbatore, , India

Site Status

The Institute of Post Graduate Medical Education & Research (IPGMER) (SSKM Hospital)

Kolkata, , India

Site Status

All India Institute of Medical Sciences (AIIMS) - New Delhi

New Delhi, , India

Site Status

Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola - Nefrologia, Dialisi e Trapianto

Bologna, , Italy

Site Status

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia - Nefrologia

Brescia, , Italy

Site Status

IRCCS Istituto Giannina Gaslini - Nefrologia e Trapianto Rene

Genova, , Italy

Site Status

Ospedale Pediatrico Bambino Gesù - Nefrologia

Roma, , Italy

Site Status

Japanese RedCross Aichi Medical Center Nagoya Daini Hospital

Nagoya, Aichi-ken, Japan

Site Status

Saitama Prefectural Children's Medical Center

Chuo-Ku, Saitama, Japan

Site Status

Kobe University Hospital

Kobe, , Japan

Site Status

Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital

Osaka, , Japan

Site Status

CSK U.M. Lodz - Klin. Nefrologii, Hipertensjologii, Transplantologii i Chorób Wewnetrznych Samodz. Publiczny Zaklad OZ

Lodz, , Poland

Site Status

Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Kliniczny Nefrologii Transplantologii i Chorob Wewnetrznych

Poznan, , Poland

Site Status

Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy - Centrum Wsparcia Badan Klinicznych

Warsaw, , Poland

Site Status

Hospital de Curry Cabral - Nephrology Department

Lisbon, , Portugal

Site Status

ULS São João - Nephrology Department

Porto, , Portugal

Site Status

Hospital de Torres Novas - Nephrology Department

Torres Novas, , Portugal

Site Status

Unidade Local de Saude de Gaia/Espinho E.P.E Nephrology Department

Vila Nova de Gaia, , Portugal

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggido, South Korea

Site Status

Seoul National University Hospital

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Hospital La Mancha Centro_Nephrology

Alcázar de San Juan, Ciudad Real, Spain

Site Status

Hospital Universitari Vall d´Hebron_ Nefrologia

Barcelona, , Spain

Site Status

Fundació Puigvert Enfermedades Renales Hereditarias. Servicio de Nefrología

Barcelona, , Spain

Site Status

Hospital Universitario Fundacion Jimenez Diaz | Nephrology and Hypertension Department

Madrid, , Spain

Site Status

Hospital Universitario Virgen del Rocio_Nephrology

Seville, , Spain

Site Status

South Tyneside and Sunderland NHS Foundation Trust | Sunderland Royal Hospital - Renal Unit

Sunderland, Tyne and Wear, United Kingdom

Site Status

Royal Devon University Healthcare NHS Foundation Trust | Royal Devon and Exeter Hospital - Renal Unit

Exeter, , United Kingdom

Site Status

Royal Free London NHS Foundation Trust | Royal Free Hospital - Centre for Nephrology

London, , United Kingdom

Site Status

Sheffield Teaching Hospitals NHS Foundation Trust | Northern General Hospital - Sheffield Kidney Institute

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Canada China Czechia France Germany India Italy Japan Poland Portugal South Korea Spain United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bayer Clinical Trials Contact

Role: CONTACT

(+)1-888-84 22937

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22419

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Everolimus on CKD Progression in ADPKD Patients
NCT01009957 TERMINATED PHASE2/PHASE3
A Clinical Trial With KJ103 in Anti-GBM Disease
NCT06607016 ACTIVE_NOT_RECRUITING PHASE2